Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 54,961 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Metastatic Melanoma, Skin Cancer, Neoplasm
Interventions: ADI PEG 20; Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York

Conditions: Advanced Cancer
Interventions: Virtual Dignity Therapy; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT; Radiation · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: Motixafortide, G-CSF; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 78 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Haematological Malignancies
Interventions: AZD0466, Voriconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions: Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines); Behavioral · Drug
Lead sponsor: Wayne State University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Endotracheal Intubation, Rapid Airway Management Positioner
Interventions: Laryngoscopy with RAMP, Laryngoscopy without RAMP; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Traumatic Brain Injury
Interventions: Animal assisted therapy; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Malignant Neoplasm, Pain
Interventions: Medical Chart Review, Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Interventions: Oral/Throat cancer test; Device
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • Memphis, Tennessee

Conditions: Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Pulmonary Embolism, Fibrinolytic Deficit
Interventions: Not listed
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Lymphoplasmacytic Lymphoma
Interventions: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide; Biological · Combination Product
Lead sponsor: BioEclipse Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • La Jolla, California • Stanford, California

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions: CTX-8371; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • Margate, Florida + 8 more

Conditions: Tinnitus
Interventions: Bimodal rTMS; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Medication Adherence, Diabetes
Interventions: PictureRx card; Behavioral
Lead sponsor: PictureRx, LLC; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: Text Message Reminder, Health Worker Visit; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain and Central Nervous System Tumors
Interventions: lonafarnib; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more

Conditions: Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III
Interventions: Hypofractionated Radiation Therapy, Radiation Boost; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions: clartihromycin, amoxicillin, and omeprazole, placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer
Interventions: calcitriol, docetaxel; Dietary Supplement · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Virtual Dignity Therapy for Palliative Care Patients With Advanced Cancer

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

Evaluation of the Rapid Airway Management Positioner

Efficacy of Animal Assisted Therapy in the Treatment of Patients With Traumatic Brain Injury

Survey of Cancer Patients' Perceptions of Difficulties Encountered When Filling Opioid Prescriptions

Validity of Viome's Oral/throat Cancer Test

A Prospective Observational Study of Foam Sclerotherapy .

Fibrinolytic Deficit in Patients With Acute PE

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

rTMS Bimodal Treatment For Tinnitus: A Pilot Study

PictureRx: An Intervention to Reduce Latino Health Disparities

Strategies for Improving Linkage-to-Care After Eye Disease Screening

SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer